EUVIMEDEUVIMED entdecken
Open Access

IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway

Yanyan Hu, Shengying Li, Minjing Zhu, Chaoju Gong iD, Zejun Fang

Molecular Carcinogenesis · 2026-09 · 65 (9) · 1126-1139

DOI: 10.1002/mc.70147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 16.07.2026. Verfasst von Yanyan Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, Sanmen People's Hospital, Sanmen, China. Hauptthemen laut MEDLINE: Oxaliplatin, Colonic Neoplasms, NF-kappa B, Drug Resistance, Neoplasm. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Zhejiang Medical and Health Science and Technology Plan, Zhejiang Provincial County Level Advantageous Disciplines of Traditional Chinese Medicine Construction Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxaliplatin‐based chemotherapy is a principal treatment for colon cancer, but drug resistance hinders its efficacy. Cancer cell dormancy is reportedly a crucial driver of chemoresistance. IL‐24 functions vitally in tumor chemoresistance, yet its role in colon cancer dormancy and oxaliplatin resistance remains unexplored.IL‐24 expression was assessed in colon cancer tissues and cells via RT‐qPCR, western blotting, or immunohistochemistry. The functions of IL‐24 in colon cancer cell proliferation, apoptosis, dormancy, and oxaliplatin resistance were evaluated by CCK‐8, flow cytometry, and western blotting. The downstream mechanism of IL‐24 was predicted using RNA sequencing and bioinformatics analyses and verified in vitro. A tumor xenograft mouse model was built to further verify the role of IL‐24 in colon cancer. IL‐24 was overexpressed in oxaliplatin‐resistant colon cancer tissues and cells. Furthermore, IL‐24 treatment reversed the anti‐proliferative and pro‐apoptotic effects of oxaliplatin on colon cancer cells. Regarding cell dormancy, IL‐24 treatment triggered G0/G1 cell cycle arrest and upregulated dormancy markers (CDKN1A, CDKN1B, TGFB2, and MSK1). Bioinformatics analyses revealed that IL‐24 might function in colon cancer mainly through NF‐κB pathway, and IL‐24 activated the NF‐κB axis in tumor cells. Importantly, treatment with NF‐κB inhibitor reversed IL‐24‐induced colon cancer cell dormancy and oxaliplatin resistance. In vivo, IL‐24 treatment abolished the anti‐tumor effects of oxaliplatin, promoted cell dormancy, and activated NF‐κB signaling in tumor tissues. IL‐24 induces colon cancer cell dormancy and oxaliplatin resistance by activating NF‐κB signaling. The IL‐24/NF‐κB axis may serve as a likely target to alleviate oxaliplatin resistance in colon cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinColonic NeoplasmsNF-kappa BDrug Resistance, NeoplasmInterleukinsHumansAnimalsInterleukin-24MiceCell ProliferationSignal TransductionApoptosisGene Expression Regulation, NeoplasticAntineoplastic AgentsXenograft Model Antitumor AssaysMaleCell Line, TumorMice, NudeFemale

Stichwörter der Autor:innen

IL‐24NF‐κBcell dormancycolon canceroxaliplatin resistance

Substanzen

OxaliplatinNF-kappa BInterleukinsInterleukin-24Antineoplastic Agents

Autor:innen und Institutionen

  • Clinical Laboratory, Sanmen People's Hospital, Sanmen, China.
  • Office of Drug Clinical Trial Institutions, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.
  • Central Laboratory, The Affiliated Xuzhou Municipal Hospital, Xuzhou Medical University, Xuzhou, China.
  • Central Laboratory, Sanmen People's Hospital, Sanmen, China.

ORCID-Profile: Chaoju Gong

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Medical and Health Science and Technology Plan
  • Zhejiang Provincial County Level Advantageous Disciplines of Traditional Chinese Medicine Construction Plan

Zitieren

APA

Hu, Y., Li, S., Zhu, M., Gong, C., & Fang, Z. (2026). IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway. Molecular Carcinogenesis, 65(9), 1126-1139. https://doi.org/10.1002/mc.70147

Vancouver

Hu Y, Li S, Zhu M, Gong C, Fang Z. IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway. Molecular Carcinogenesis. 2026;65(9):1126-1139. doi:10.1002/mc.70147

BibTeX
@article{Hu2026,
  author = {Hu, Yanyan and Li, Shengying and Zhu, Minjing and Gong, Chaoju and Fang, Zejun},
  title = {IL‐24 Induces Cell Dormancy and Oxaliplatin Resistance in Colon Cancer Cells by Activating NF‐κB Pathway},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  volume = {65},
  number = {9},
  pages = {1126--1139},
  doi = {10.1002/mc.70147}
}
Kostenlos starten →